Related references
Note: Only part of the references are listed.IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro
Aruna Gowda et al.
BLOOD (2008)
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
Esther Moga et al.
EXPERIMENTAL HEMATOLOGY (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
G. Maki et al.
LEUKEMIA (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
Nuzhat I. Pathan et al.
BLOOD (2008)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Narrative review: Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia
Tait D. Shanafelt et al.
ANNALS OF INTERNAL MEDICINE (2006)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Monoclonal antibody therapy of chronic lymphocytic leukemia
BD Cheson
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Chronic lymphocytic leukemia: Recent advances in diagnosis and treatment
Brian L. Abbott
ONCOLOGIST (2006)
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
A Iannello et al.
CANCER AND METASTASIS REVIEWS (2005)
Novel immune-based treatment strategies for chronic lymphocytic leukemia
WG Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Natural killer lymphocytes: biology, development, and function
M Papamichail et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship
S Dall'Ozzo et al.
CANCER RESEARCH (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
LE van der Kolk et al.
LEUKEMIA (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Share Paper
